Signature

<b>X</b>	04-	1	7	



PTO/SB/05 (03-01) Approved for use through 10/31/2002. OMB 0651-0032

Please type a plus sign (+) inside this box -

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## UTILITY PATENT APPLICATION TRANSMITTAL

PAN01/003 Attorney Docket No. Merril First Inventor Methods for Treating Prion. Title

(Only for new nonprovisional applications under 37 CFR 1.53(b))

EF393302401US Express Mail Label No

Assistant Commissioner for Patents **APPLICATION ELEMENTS** ADDRESS TO: **Box Patent Application** Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Fee Transmittal Form (e.g., PTO/SB/17) CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix) Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) (preferred arrangement set forth below) Computer Readable Form (CRF) a. - Descriptive title of the invention b. Specification Sequence Listing on: - Cross Reference to Related Applications CD-ROM or CD-R (2 copies); or - Statement Regarding Fed sponsored R & D - Reference to sequence listing, a table, paper or a computer program listing appendix - Background of the Invention Statements verifying identity of above copies - Brief Summary of the Invention ACCOMPANYING APPLICATION PARTS - Brief Description of the Drawings (if filed) - Detailed Description Assignment Papers (cover sheet & document(s)) 9. - Claim(s) 37 CFR 3.73(b) Statement Power of - Abstract of the Disclosure 10. (when there is an assignee) Attorney English Translation Document (if applicable) Drawing(s) (35 U.S.C. 113) [ Total Sheets Copies of IDS Information Disclosure 12. 5. Oath or Declaration [ Total Pages Citations Statement (IDS)/PTO-1449 Newly, executed (original or copy)
Copy from a prior application (37 CFR 1.63 (d))
(for continuation/divisional with Box 18 completed) 13 Preliminary Amendment Return Receipt Postcard (MPEP 503) b. (Should be specifically itemized) Certified Copy of Priority Document(s) (if foreign priority is claimed) **DELETION OF INVENTOR(S)** 15. Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 122 named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b). (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent. Application Data Sheet. See 37 CFR 1.76 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: Continuation Continuation-in-part (CIP) of prior application No.:\_\_\_\_/\_ Prior application information: For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS Correspondence address below Customer Number or Bar Code Label (Insert Customer No. or Attach bar code label here) Mary E. Gormley Name Panacea Pharmaceuticals, 9700 Great Seneca Hwy. Address Rockville City State Maryland Zip Code 20850 Country US Telephone Fax (240)453-8496240)465-0**4**50 Mary E. Gormley 34,409 Name (Print/Type) Registration No. (Attorney/Agent)

Burden Hour Statement: This form is estimated to the 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

PTO/SB/17 (11-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it displays a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to r

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT

(\$) 35	55.	0	0
---------	-----	---	---

	ompl t if Known	
Application Number		
Filing Date	April 16, 2001 (herewi	:h)
First Named Inventor	Merril	
Examiner Name		
Group Art Unit		
Attorney Docket No.	PAN01/003	

METHOD OF PAYMENT				FE	E CALCULATION (continued)		
The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to:		3. ADDITIONAL FEES					
Deposit		Larg Entit		Sma Entit			
Account Number	Fee Cod	Fee	Fee Cod	Fee	Fee Description	Fee Paid	
Deposit Account Name	105	130	205	65	Surcharge - late filing fee or oath		
Charge Any Additional Fee Required Under 37 CFR 1,16 and 1,17		50	227	25	Surcharge - late provisional filing fee or cover sheet		
Y Applicant claims small entity status.	139	130	139	130	Non-English specification		
See 37 CFR 1.27	147	2,520	147	2,520	For filing a request for ex parte reexamination		
2. XX Payment Enclosed:  V Check Credit card Order Other	112	920*	112	920*	Requesting publication of SIR prior to Examiner action		
FEE CALCULATION		1,840*	113	1,840	Requesting publication of SIR after Examiner action		
1. BASIC FILING FEE	115	110	215	55	Extension for reply within first month		
Large Entity Small Entity	116	390	216	195	Extension for reply within second month		
Fee Fee Fee Fee Description	117	890	217	445	Extension for reply within third month		
Code (\$) Code (\$) Fee Paid  101 710 201 355 Utility filing fee 355	118	1,390	218	695	Extension for reply within fourth month		
106 320 206 160 Design filing fee	128	1,890	228	945	Extension for reply within fifth month		
107 490 207 245 Plant filing fee	119	310	219	155	Notice of Appeal		
108 710 208 355 Reissue filing fee	120	310	220	155	Filing a brief in support of an appeal		
114 150 214 75 Provisional filing fee	121	270	221	135	Request for oral hearing		
	138	1,510	138	1,510	Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 355.00		110	240	55	Petition to revive - unavoidable		
2. EXTRA CLAIM FEES		1,240	241	620	Petition to revive - unintentional		
Fee from Extra Claims below Fee Paid	142	1,240	242	620	Utility issue fee (or reissue)		
Otal Claims 18 -20** = X =	143	440	243	220	Design issue fee		
ndependent 1 - 3** = X = =	144	600	244	300	Plant issue fee		
Multiple Dependent =	122	130	122	130	Petitions to the Commissioner		
<del></del>	123	50	123	50	Processing fee under 37 CFR 1.17(q)		
Large Entity Small Entity Fee Fee Fee Fee Description	126	180	126	180	Submission of Information Disclosure Stmt		
Code (\$) Code (\$)  103 18 203 9 Claims in excess of 20	581	40	581	40	Recording each patent assignment per property (times number of properties)		
102 80 202 40 Independent claims in excess of 3	146	710	246	355	Filing a submission after final rejection (37 CFR § 1.129(a))		
104 270 204 135 Multiple dependent claim, if not paid	149	710	249	355	For each additional invention to be		
109 80 209 40 ** Reissue independent claims over original patent	'~	, 10	240	000	examined (37 CFR § 1.129(b))		
110 18 210 9 ** Reissue claims in excess of 20	179	710	279	355	Request for Continued Examination (RCE)		
and over original patent	169	900	169	900	Request for expedited examination of a design application		
SUBTOTAL (2) (\$)	Other	r fee (s	pecify	)		<u> </u>	
**or number previously paid, if greater; For Reissues, see above *Reduced by Basic Filing Fee Paid *SUBTOTAL (3) (\$)							

SUBMITTED BY		Complete (if	Complete (if applicable)		
Name (Print/Type)	Mary E. Gormley	Registration No. (Attorney/Agent) 34,409	Telephone		
Signature	Maus 9. Sorme	Les	Date	4/16/01	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.